Aclaris Therapeutics (ACRS) vs Alumis (ALMS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed Alumis (ALMS) over the past year, gaining 37.1% versus a loss of 45.8%. Aclaris Therapeutics is the larger company by market cap ($545.6 million vs $514.1 million), about 1.1 times the size. Aclaris Therapeutics converts more of its revenue into profit, with a net margin of -829.6% versus -1011.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | ALMS |
|---|---|---|
| Share price | $3.44 | $3.96 |
| Market cap | $545.63M | $514.09M |
| 1-day change | -1.71% | -8.55% |
| YTD return | +14.29% | -59.43% |
| 1-year return | +37.05% | -45.75% |
| 5-year return | -72.74% | — |
| EPS (TTM) | $-0.59 | $-3.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.83M | $24.05M |
| Revenue growth (YoY) | -58.19% | — |
| Net income (latest FY) | $-64.92M | $-243.32M |
| Gross margin | 73.28% | — |
| Operating margin | -975.91% | -1886.92% |
| Net margin | -829.58% | -1011.75% |
| 52-week high | $6.60 | $31.35 |
| 52-week low | $2.46 | $3.94 |
| Distance from 52-week high | -47.88% | -87.37% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +205.23% | +540.91% |
| Average volume | 3.07M | 2.87M |
| Shares outstanding | 158.61M | 129.82M |
| Employees | 69 | 251 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed ALMS by 82.8 percentage points over the past year.
- Aclaris Therapeutics is more profitable, keeping -829.6 cents of every revenue dollar as net income versus -1011.7 cents for Alumis.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 251 employees
ACRS vs ALMS FAQ
Which is bigger, Aclaris Therapeutics or Alumis?
Aclaris Therapeutics (ACRS) is larger, with a market capitalization of $545.63M compared with $514.09M for Alumis (ALMS).
Which stock has performed better over the past year, ACRS or ALMS?
ACRS returned +37.05% over the past 12 months, compared with -45.75% for ALMS (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and Alumis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.